BENDAMUSTİN+ POMALİDOMİD+ DEKSAMETAZON

Kaynaklar:

1- Dharshan Sivaraj et al. Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma. Blood Cancer J . 2018 Jul 31;8(8):71.

2- Lentzsch S, et al. Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study. Blood. 2012;119:4608–4613.

3-Leoni LM. The evolving role of bendamustine in lymphoid malignancy: understanding the drug and its mechanism of action--introduction. Semin. Hematol. 2011;48(Suppl 1):S1–S3.

4-Knop S, et al. The efficacy and toxicity of bendamustine in recurrent multiple myeloma after high-dose chemotherapy. Haematologica. 2005;90:1287–1288.

5-Ramasamy K, Hazel B, Mahmood S, Corderoy S, Schey S. Bendamustine in combination with thalidomide and dexamethasone is an effective therapy for myeloma patients with end stage renal disease. Br. J. Haematol. 2011;155:632–634.

6-Pönisch W, et al. Lenalidomide, bendamustine and prednisolone exhibits a favourable safety and efficacy profile in relapsed or refractory multiple myeloma: final results of a phase 1 clinical trial OSHO - #077. Br. J. Haematol. 2013;162:202–209.

7-Berensen JR, et al. Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. Br. J. Haematol. 2013;160:321–330.

8-Gramatzki M, et al. Carfilzomib in combination with bendamustine and dexamethasone (CBd) in relapsed and/or refractory patients with multiple myeloma: the phase I/II EMN09 study. Blood J. 2016;128:3334.